Marcia Belvin - Dec 17, 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
SVP, Chief Scientific Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Marcia Belvin
Stock symbol
CTMX
Transactions as of
Dec 17, 2023
Transactions value $
$0
Form type
4
Date filed
12/19/2023, 07:54 PM
Previous filing
Sep 22, 2023
Next filing
Dec 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Options Exercise $0 +11.3K +7.6% $0.00 159K Dec 17, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Performance Stock Units (PSUs) Options Exercise $0 -11.3K -50% $0.00 11.3K Dec 17, 2023 Common Stock 11.3K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
F2 Includes 116,875 restricted stock units.
F3 Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.